JP6112316B2 - テトラアザ−シクロペンタ［ａ］インデニル及びポジティブアロステリックモジュレーターとしてのそれらの使用 - Google Patents

テトラアザ−シクロペンタ［ａ］インデニル及びポジティブアロステリックモジュレーターとしてのそれらの使用 Download PDF

Info

Publication number
JP6112316B2
JP6112316B2 JP2014547736A JP2014547736A JP6112316B2 JP 6112316 B2 JP6112316 B2 JP 6112316B2 JP 2014547736 A JP2014547736 A JP 2014547736A JP 2014547736 A JP2014547736 A JP 2014547736A JP 6112316 B2 JP6112316 B2 JP 6112316B2
Authority
JP
Japan
Prior art keywords
mmol
title compound
tetraaza
cyclopenta
hplc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014547736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502371A5 (enExample
JP2015502371A (ja
Inventor
ドミニク スウィンネン
ドミニク スウィンネン
シリル モンターニュ
シリル モンターニュ
ヴァンサン ポメル
ヴァンサン ポメル
アンナ クアトロパーニ
アンナ クアトロパーニ
ジェローム モレット
ジェローム モレット
パトリック ゲルバー
パトリック ゲルバー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11195214.9A external-priority patent/EP2607364A1/en
Priority claimed from EP12171415.8A external-priority patent/EP2674434A1/en
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2015502371A publication Critical patent/JP2015502371A/ja
Publication of JP2015502371A5 publication Critical patent/JP2015502371A5/ja
Application granted granted Critical
Publication of JP6112316B2 publication Critical patent/JP6112316B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2014547736A 2011-12-22 2012-11-30 テトラアザ−シクロペンタ［ａ］インデニル及びポジティブアロステリックモジュレーターとしてのそれらの使用 Active JP6112316B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161578931P 2011-12-22 2011-12-22
EP11195214.9 2011-12-22
EP11195214.9A EP2607364A1 (en) 2011-12-22 2011-12-22 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
US61/578,931 2011-12-22
US201261657978P 2012-06-11 2012-06-11
EP12171415.8A EP2674434A1 (en) 2012-06-11 2012-06-11 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
US61/657,978 2012-06-11
EP12171415.8 2012-06-11
PCT/EP2012/004968 WO2013091773A1 (en) 2011-12-22 2012-11-30 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators

Publications (3)

Publication Number Publication Date
JP2015502371A JP2015502371A (ja) 2015-01-22
JP2015502371A5 JP2015502371A5 (enExample) 2016-08-04
JP6112316B2 true JP6112316B2 (ja) 2017-04-12

Family

ID=48667735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014547736A Active JP6112316B2 (ja) 2011-12-22 2012-11-30 テトラアザ−シクロペンタ［ａ］インデニル及びポジティブアロステリックモジュレーターとしてのそれらの使用

Country Status (8)

Country Link
US (1) US9403835B2 (enExample)
EP (1) EP2794608B1 (enExample)
JP (1) JP6112316B2 (enExample)
CN (1) CN104039789B (enExample)
AU (1) AU2012357169B2 (enExample)
CA (1) CA2860008C (enExample)
ES (1) ES2606839T3 (enExample)
WO (1) WO2013091773A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2813505A1 (en) * 2013-06-14 2014-12-17 Asceneuron SA Tetraaza-cyclopenta[a]indenyl derivatives
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
US9844549B2 (en) 2014-08-26 2017-12-19 Astellas Pharma Inc. 2-aminothiazole derivative or salt thereof
UA123262C2 (uk) * 2015-02-11 2021-03-10 Суновіон Фармасьютикалз Інк. ЗШИТІ ДИГІДРО-4H-ПІРАЗОЛО[5,1-c][1,4]ОКСАЗИНІЛОВІ СПОЛУКИ І АНАЛОГИ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАНЬ ЦНС
WO2017038650A1 (ja) * 2015-08-28 2017-03-09 積水メディカル株式会社 ベンジル化合物
EA201990399A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения, композиции и их применение
CN111183138A (zh) 2017-08-02 2020-05-19 赛诺维信制药公司 异色满化合物以及用途
BR112020012197A2 (pt) 2017-12-21 2020-11-24 Ribon Therapeutics Inc. quinazolinonas como inibidores de parp14

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441926A1 (en) * 2001-03-27 2002-10-03 Neurogen Corporation (oxo-pyrazolo[1,5a]pyrimidin-2-yl)alkyl-carboxamides
MX2007006896A (es) * 2004-12-15 2007-06-26 Hoffmann La Roche Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer.
JP5232160B2 (ja) * 2006-11-14 2013-07-10 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしての三環式芳香族複素環化合物
WO2011137049A1 (en) * 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Heterocyclic quinolizine derived m1 receptor positive allosteric modulators
EP2813505A1 (en) * 2013-06-14 2014-12-17 Asceneuron SA Tetraaza-cyclopenta[a]indenyl derivatives

Also Published As

Publication number Publication date
ES2606839T3 (es) 2017-03-28
CA2860008C (en) 2020-11-10
US9403835B2 (en) 2016-08-02
CN104039789A (zh) 2014-09-10
EP2794608B1 (en) 2016-09-14
US20150018343A1 (en) 2015-01-15
AU2012357169A1 (en) 2014-08-07
JP2015502371A (ja) 2015-01-22
AU2012357169B2 (en) 2017-03-30
CN104039789B (zh) 2016-09-07
WO2013091773A1 (en) 2013-06-27
EP2794608A1 (en) 2014-10-29
CA2860008A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
JP6112316B2 (ja) テトラアザ−シクロペンタ［ａ］インデニル及びポジティブアロステリックモジュレーターとしてのそれらの使用
EP0239309B1 (en) Oxadiazoles useful in the treatment of senile dementia
JP7289301B2 (ja) ４－アザインドール化合物
TWI468402B (zh) 降低β－類澱粉生成之化合物
EP3538526B1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
RU2448105C2 (ru) 2-аминобензоксазолкарбоксамиды в качестве модуляторов 5-нт3
CA2683598C (en) 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
EP3844159B1 (en) Novel pyrrolidinyl amide compounds for the treatment of autoimmune disease
CA2745721C (en) Substituted piperidine spiro pyrrolidinone and piperidinones used as h3 modulators
CA2704320A1 (en) Aryl-substituted bridged or fused diamines as modulators of leukotriene a4 hydrolase
AU2003214503A1 (en) Tropane derivatives as ccr5 modulators
BRPI0911336A2 (pt) tiazolopiridin-2-iloxifenil e tiazolopirazin-2-iloxifenil aminas como moduladores de leucotrieno a4 hidrolase
EP3847165A1 (en) Novel pyrrolidine amine compounds for the treatment of autoimmune disease
AU2006236625A1 (en) N-alkyl-azacycloalkyl NMDA/NR2B antagonists
TW202310831A (zh) 作為Kv1.3鉀SHAKER離子通道阻斷劑之螺吲哚啉酮化合物
EP2989104B1 (en) Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments
JP2024536237A (ja) Ｔｒｐｍｌの調整剤、その組成物及び使用方法
EP3008068B1 (en) Tetraaza-cyclopenta[a]indenyl derivatives
EP2674434A1 (en) Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
EP2607364A1 (en) Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
TW202508565A (zh) Kv1.3鉀通道拮抗劑
HK40043697A (en) Novel pyrrolidine amine compounds for the treatment of autoimmune disease

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170228

R150 Certificate of patent or registration of utility model

Ref document number: 6112316

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250